NCT06186492View on ClinicalTrials.gov

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
DRUG

WVE-006

RNA editing oligonucleotide

Trial Locations (1)

CF48 4DR

Simbec-Orion Clinical Pharmacology,, Merthyr Tydfil

All Listed Sponsors
lead

Wave Life Sciences Ltd.

INDUSTRY

NCT06186492 - A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) | Biotech Hunter | Biotech Hunter